LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ:MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.